Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure

Category Primary study
JournalRheumatology (United Kingdom)
Year 2014
This article has no abstract
Epistemonikos ID: d7e490200a0149764854c223ae2f542e6b36d306
First added on: Feb 15, 2022